Alzheimer Disease / Magnetic Resonance Imaging / Neurodegenerative Diseases · Observational Study

Memory Deterioration in Alzheimer Disease

ClinicalTrials.gov · August 13, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a recruiting observational registry record from a Norwegian academic centre studying individual differences in Alzheimer disease using multimodal biomarkers (7T MRI, EEG, blood and stool samples, neuropsychology) over 1 year. No results are posted; the study is in the recruitment phase and carries no current evidence on clinical outcomes or efficacy.

What was studied

Observational. Alzheimer Disease, Neurodegenerative Diseases, Magnetic Resonance Imaging, Memory Impairment; age from 55 Years; accepts healthy volunteers. Intervention: Mild Alzheimer; Controls. Compared with: Healthy controls (implied from primary outcome statement, but not formally detailed in registry text).. n = 30. 1 site: Norway.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a recruiting observational study with no results posted; it represents planned work in an early phase that will require completion and analysis before evidence can be judged.

Study design

As stated by the source record.

MethodsCohort model. Prospective time perspective. Primary outcome measures: Understand which individual differences are observed among patients with Alzheimer's disease (AD). (assessed at From enrollment to end of follow-up at 1 year.); Compare changes in the brain, blood, and stool samples between dementia patients and healthy controls. (assessed at From project enrollment to end of follow-up at 1 year.)

DesignObservational

PopulationAlzheimer Disease, Neurodegenerative Diseases, Magnetic Resonance Imaging, Memory Impairment; age from 55 Years; accepts healthy volunteers

Sample size30

InterventionMild Alzheimer; Controls

ComparatorHealthy controls (implied from primary outcome statement, but not formally detailed in registry text).

Setting1 site: Norway

Reported figures

Quoted from the source exactly as published.

Planned enrollment30

Follow-up duration1 year

Primary outcome measure 1Understand which individual differences are observed among patients with Alzheimer's disease (AD), from enrollment to end of follow-up at 1 year

Primary outcome measure 2Compare changes in the brain, blood, and stool samples between dementia patients and healthy controls, from project enrollment to end of follow-up at 1 year

Caveats

This is a registry record only; no results are posted or analysed.
Sample size is small (n=30 estimated) and may limit statistical power.
Study status is recruiting; completion date, actual enrollment, retention, and analytical approach not yet reported.
No comparator group composition, inclusion/exclusion criteria, or outcome definitions detailed in registry text.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Observational design without randomization or blinding; no control arm explicitly stated.

Directness

moderate

Measures neuropsychology, imaging, and biomarkers directly relevant to AD pathology and cognition.

Consistency

insufficient

No results reported; consistency cannot be assessed against other studies.

Risk of bias

insufficient

Study is recruiting; conduct, blinding, and completion unknown; bias risk cannot yet be judged.

Sample adequacy

limited

Estimated 30 participants total; small sample size for observational biomarker study.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07118137). This is a study registration, not published results. Lead sponsor: Norwegian University of Science and Technology. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 30 participants (ESTIMATED). Conditions: Alzheimer Disease, Neurodegenerative Diseases, Magnetic Resonance Imaging, Memory Impairment. Interventions: DEVICE: 7T MRI; DEVICE: EEG; BIOLOGICAL: Blood samples; BIOLOGICAL: Stool samples; DIAGNOSTIC_TEST: Neuropsychologic test (MoCA). Primary outcome measures: Understand which individual differences are observed among patients with Alzheimer's disease (AD). , From enrollment to end of follow-up at 1 year.; Compare changes in the brain, blood, and stool samples between dementia patients and healthy controls. , From project enrollment to end of follow-up at 1 year.. Brief summary: Semantic AD

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Alzheimer DiseaseNCT07118137Magnetic Resonance ImagingNeurodegenerative Diseases7T MRINorwegian University of Science and TechnologyEEGStool samplesBlood samples